SiBionics and PharmaSens Explore Automated Insulin Delivery at EASD 2026
SiBionics presented its "See More, Act Sooner" concept at EASD 2026, integrating continuous glucose monitoring with future diabetes care. Collaboration with PharmaSens focuses on automated insulin delivery.
SiBionics, a company focused on diabetes care, presented new possibilities in automated insulin delivery at the European Association for the Study of Diabetes (EASD) annual meeting in 2026. The company highlighted its "See More, Act Sooner" initiative, which aims to combine continuous glucose monitoring (CGM) technology with future diabetes management strategies.
The presentation at the event centered on the integration of CGM technology and forward-looking treatment approaches. The goal is to enhance the quality of life for individuals with diabetes by more effectively anticipating and responding to blood glucose fluctuations. SiBionics has partnered with PharmaSens to develop novel solutions for automating insulin delivery.
The utilization of CGM technology provides real-time data on glucose levels, enabling individuals and healthcare professionals to make informed decisions. SiBionics' concepts suggest a move towards systems capable of autonomously adjusting insulin delivery based on glucose and other physiological data.
The collaboration between SiBionics and PharmaSens is expected to accelerate the development of automated treatment systems. Such systems could significantly reduce the daily burden of diabetes management and improve blood glucose control, thereby lowering the risk of long-term complications.